PIVLAZ is indicated for preventing cerebral vasospasm in aneurysmal subarachnoid haemorrhage (aSAH) patients. Credit: Kateryna Kon/Shutterstock.com.

Nxera Pharma Korea has entered into a strategic supply and distribution partnership with Handok for the marketing of PIVLAZ (clazosentan sodium) 150mg within the South Korean market.

PIVLAZ is indicated for preventing cerebral vasospasm in aSAH patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Under the terms of the collaboration, Nxera Pharma Korea will be in charge of supplying PIVLAZ to Handok at a predetermined price.

Handok will assume full responsibility for promotiion, marketing, sales and distribution of the drug product in South Korea.

As per the deal, Nxera is entitled to receive an upfront payment from Handok.

Additionally, Handok will make commercial milestone payments and revenues generated from the product supply to Nxera.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PIVLAZ is said to be the first medication approved in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms following aSAH.

Its commercial availability in South Korea is expected to begin early next year, providing a new therapeutic option for patients affected by aSAH and the associated risk of cerebral vasospasm.

Nxera executive officer, executive vice-president and Nxera Pharma Korea chairman Satoshi Tanaka said: “We are pleased to be continuing our long-standing partnership with Handok to bring PIVLAZ to patients in South Korea.

“PIVLAZ represents a potentially life-changing treatment option for patients and Handok’s wealth of expertise and history of delivering products to the Korean market makes them the ideal partner.

“With this partnership in place, we are confident that we will be able to deliver PIVLAZ to physicians and patients in South Korea in early 2025.”